Addressing scaling-up limitations: optimized PEI-mediated production of clinical grade viral vectorsPublished: March 26, 2018
Latest Developments in Viral and Non-Viral Vector Manufacturing
Alengo Nyamay’Antu, Valérie Kedinger & Patrick Erbacher
With the progress in developing new viral vector systems guided by safety, specificity and potency considerations, several gene and cell-based therapies are now close to being clinically approved and commercially available to treat genetic diseases. These viral vectors systems are based on the production of mainly adeno-associated viruses (AAV) and lentiviruses by transient transfection of human embryonic kidney (HEK)-293 derived producer cell lines. Virus vector production using the right transient transfection method is crucial to provide the flexibility and reproducibility that is needed to scale-up from initial process development to manufacturing of high-quality grade viral vectors. PEI-mediated transient transfection is an efficient and cost-effective approach to produce viral vectors. With the available quality grades of PEI, PEIpro® and PEIpro-HQ®, Polyplus-transfection offers a reliable PEI transfection method suitable for process development up to viral vector production for clinical and commercial manufacturing.DOI: 10.18609/cgti.2018.013
Citation: Cell Gene Therapy Insights 2018; 4(2), 71-79.